Study of Weekly Cabazitaxel for Advanced Prostate Cancer

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: kidneytreatment withpriorckdtreated
  Phrases that lowered it: advancedprostateclinicalto evaluatedocetaxel
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 38.0% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 96.7% (raises risk) · Drug's FDA history
• Sponsor's past trials: 2 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Keywords listed: 3 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen NCT01254279 · started 2010 · scored riskier than 40% of active trials completed
• Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer NCT01324583 · started 2011 · scored riskier than 16% of active trials completed
• Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT02844582 · started 2017 · scored riskier than 52% of active trials terminated
• A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer NCT01541007 · started 2012 · scored riskier than 90% of active trials completed
• Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer NCT01308580 · started 2011 · scored riskier than 18% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.